{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:48:17Z","timestamp":1776235697272,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:00:00Z","timestamp":1538006400000},"content-version":"am","delay-in-days":330,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural National Science Foundation of China (NSFC","doi-asserted-by":"publisher","award":["81303251"],"award-info":[{"award-number":["81303251"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"Natural National Science Foundation of China (NSFC","doi-asserted-by":"publisher","award":["81673407"],"award-info":[{"award-number":["81673407"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2015A030313317"],"award-info":[{"award-number":["2015A030313317"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004377","name":"PolyU","doi-asserted-by":"publisher","award":["G-YZ95"],"award-info":[{"award-number":["G-YZ95"]}],"id":[{"id":"10.13039\/501100004377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002920","name":"Research Grants Council of Hong Kong","doi-asserted-by":"publisher","award":["15101014"],"award-info":[{"award-number":["15101014"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ITSP-Guangdong-Hong Kong Technology Cooperation Funding Scheme","award":["GHP\/012\/16GD"],"award-info":[{"award-number":["GHP\/012\/16GD"]}]},{"name":"Shenzhen Basic Research Program","award":["JCYJ20160331141459373"],"award-info":[{"award-number":["JCYJ20160331141459373"]}]},{"DOI":"10.13039\/501100010031","name":"China Postdoctoral Science Foundation Grant","doi-asserted-by":"publisher","award":["2015M570753"],"award-info":[{"award-number":["2015M570753"]}],"id":[{"id":"10.13039\/501100010031","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006469","name":"Science and Technology Development Fund (FDCT) of Macao SAR","doi-asserted-by":"publisher","award":["134\/2014\/A3"],"award-info":[{"award-number":["134\/2014\/A3"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"Research Committee of University of Macau","doi-asserted-by":"publisher","award":["MYRG2016-00129-ICMS-QRCM"],"award-info":[{"award-number":["MYRG2016-00129-ICMS-QRCM"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"Macau Young Scholars Collaborative Research Fund by the Natural National Science Foundation of China","doi-asserted-by":"publisher","award":["81328025"],"award-info":[{"award-number":["81328025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.neuropharm.2017.08.014","type":"journal-article","created":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T14:45:13Z","timestamp":1502549113000},"page":"12-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Substantial protection against MPTP-associated Parkinson's neurotoxicity in\u00a0vitro and in\u00a0vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B"],"prefix":"10.1016","volume":"126","author":[{"given":"Baojian","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengquan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyou","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangcheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xifei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guozhen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinghung","family":"Mak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony Chung-Lit","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmond Dik-Lung","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon Ming Yuen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaijun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.08.014_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2174\/157015911795596577","article-title":"Medical management of Parkinson's disease: focus on neuroprotection","volume":"9","author":"Boll","year":"2011","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030551","article-title":"Parkinson's disease: from pathogenesis to pharmacogenomics","volume":"18","author":"Cacabelos","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s12035-016-9818-1","article-title":"MEF2D mediates the neuroprotective effect of methylene blue against glutamate-induced oxidative damage in HT22 hippocampal cells","volume":"54","author":"Chen","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.nbd.2010.08.022","article-title":"alpha-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease","volume":"41","author":"Chu","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.08.014_bib6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/bph.12004","article-title":"The anti-cancer agent SU4312 unexpectedly protects against MPP(+) -induced neurotoxicity via selective and direct inhibition of neuronal NOS","volume":"168","author":"Cui","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10522-014-9523-2","article-title":"Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence","volume":"15","author":"Driver","year":"2014","journal-title":"Biogerontology"},{"key":"10.1016\/j.neuropharm.2017.08.014_bib8","article-title":"Quantified assessment of terminal density and innervation","volume":"13","author":"Finkelstein","year":"2004","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib9","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1021\/acs.jafc.6b01707","article-title":"Multifunction of chrysin in Parkinson's model: anti-neuronal apoptosis, neuroprotection via activation of MEF2D, and inhibition of monoamine oxidase-B","volume":"64","author":"Guo","year":"2016","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib10","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1073\/pnas.0511321103","article-title":"Neuroprotection by pharmacologic blockade of the GAPDH death cascade","volume":"103","author":"Hara","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib11","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","article-title":"Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of alpha-synuclein in Parkinson's disease models","volume":"22","author":"Hebron","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib12","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1021\/acschemneuro.5b00108","article-title":"Substantial neuroprotective and neurite outgrowth-promoting activities by bis(propyl)-cognitin via the activation of Alpha7-nAChR, a promising anti-Alzheimer's dimer","volume":"6","author":"Hu","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s12031-015-0638-y","article-title":"Indirubin-3-oxime effectively prevents 6OHDA-induced neurotoxicity in PC12 cells via activating MEF2D through the inhibition of GSK3beta","volume":"57","author":"Hu","year":"2015","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bbr.2016.07.028","article-title":"beta-asarone increases MEF2D and TH levels and reduces alpha-synuclein level in 6-OHDA-induced rats via regulating the HSP70\/MAPK\/MEF2D\/Beclin-1 pathway: chaperone-mediated autophagy activation, macroautophagy inhibition and HSP70 up-expression","volume":"313","author":"Huang","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib15","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1038\/srep04874","article-title":"The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease","volume":"4","author":"Karuppagounder","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.2199","article-title":"Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease","volume":"16","author":"Lee","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib17","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/hmg\/ddt674","article-title":"c-Abl phosphorylates alpha-synuclein and regulates its degradation: implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's disease","volume":"23","author":"Mahul-Mellier","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib18","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1073\/pnas.96.10.5774","article-title":"Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism","volume":"96","author":"Mandir","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jcp.22129","article-title":"Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells","volume":"224","author":"Miki","year":"2010","journal-title":"J.\u00a0Cell Physiol."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib20","doi-asserted-by":"crossref","first-page":"14362","DOI":"10.1074\/jbc.M112.439216","article-title":"Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)","volume":"288","author":"Mount","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1212\/WNL.0b013e31829c5ec1","article-title":"Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study","volume":"81","author":"Musicco","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.08.014_bib22","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1212\/WNL.47.6_Suppl_3.200S","article-title":"Role of selegiline in combination therapy of Parkinson's disease","volume":"47","author":"Myllyla","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2017.08.014_bib23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.celrep.2014.06.005","article-title":"S-nitrosylation-mediated redox transcriptional switch modulates neurogenesis and neuronal cell death","volume":"8","author":"Okamoto","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib24","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.18632\/oncotarget.6223","article-title":"MEF2 transcription factors: developmental regulators and emerging cancer genes","volume":"7","author":"Pon","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.neuropharm.2017.08.014_bib25","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1007\/s12035-016-9980-5","article-title":"Caspase-1 deficiency alleviates dopaminergic neuronal death via inhibiting caspase-7\/AIF pathway in MPTP\/p mouse model of Parkinson's disease","volume":"54","author":"Qiao","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib26","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.23714","article-title":"Milestones in Parkinson's disease therapeutics","volume":"26","author":"Rascol","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/gbb.12058","article-title":"Emerging roles for MEF2 transcription factors in memory","volume":"13","author":"Rashid","year":"2014","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib28","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bmc.2014.12.063","article-title":"Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques","volume":"23","author":"Rojas","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2006.07.020","article-title":"Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism","volume":"25","author":"Sagi","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1172\/JCI43871","article-title":"Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients","volume":"121","author":"She","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1523\/JNEUROSCI.2875-05.2006","article-title":"Calpain-regulated p35\/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2","volume":"26","author":"Smith","year":"2006","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib32","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/jm980123i","article-title":"Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases","volume":"41","author":"Sun","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrn3464","article-title":"Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders","volume":"14","author":"Tabares-Seisdedos","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fncel.2014.00050","article-title":"A\u00a0novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease","volume":"8","author":"Tanabe","year":"2014","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib35","doi-asserted-by":"crossref","first-page":"a009316","DOI":"10.1101\/cshperspect.a009316","article-title":"A\u00a0guide to neurotoxic animal models of Parkinson's disease","volume":"1","author":"Tieu","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib36","doi-asserted-by":"crossref","first-page":"11386","DOI":"10.1158\/0008-5472.CAN-07-3126","article-title":"Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish","volume":"67","author":"Tran","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneurol.2013.132","article-title":"Advances in the genetics of Parkinson disease","volume":"9","author":"Trinh","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib38","doi-asserted-by":"crossref","first-page":"32619","DOI":"10.1074\/jbc.M109.067785","article-title":"Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis","volume":"284","author":"Wang","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib39","first-page":"457","article-title":"Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety","author":"Weinreb","year":"2006","journal-title":"J.\u00a0Neural Transm. Suppl."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib40","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","article-title":"Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity","volume":"92","author":"Weinreb","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib41","doi-asserted-by":"crossref","first-page":"5757","DOI":"10.1111\/bph.12875","article-title":"Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders","volume":"171","author":"Wrasidlo","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib42","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1749-6632.2000.tb06191.x","article-title":"Effect of MAO-B inhibitors on MPP+ toxicity in\u00a0Vivo","volume":"899","author":"Wu","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2017.08.014_bib43","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.1166088","article-title":"Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy","volume":"323","author":"Yang","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.08.014_bib44","doi-asserted-by":"crossref","first-page":"34246","DOI":"10.1074\/jbc.M112.367540","article-title":"Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects","volume":"287","author":"Yao","year":"2012","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817303817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T12:14:17Z","timestamp":1712319257000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817303817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":44,"alternative-id":["S0028390817303817"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.014","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substantial protection against MPTP-associated Parkinson's neurotoxicity in\u00a0vitro and in\u00a0vivo by anti-cancer agent SU4312 via activation of MEF2D and inhibition of MAO-B","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}